Compare TECX & ARDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TECX | ARDC |
|---|---|---|
| Founded | 2019 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.0M | 317.5M |
| IPO Year | 2018 | N/A |
| Metric | TECX | ARDC |
|---|---|---|
| Price | $20.57 | $13.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $80.40 | N/A |
| AVG Volume (30 Days) | ★ 327.4K | 115.8K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.84% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.70 | $11.56 |
| 52 Week High | $61.07 | $14.30 |
| Indicator | TECX | ARDC |
|---|---|---|
| Relative Strength Index (RSI) | 50.43 | 52.21 |
| Support Level | $18.99 | $13.24 |
| Resistance Level | $21.86 | $13.42 |
| Average True Range (ATR) | 1.28 | 0.10 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 53.26 | 81.82 |
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).